Notizia - Recent Pharma, Healthcare and Biotech Happenings

pharma-news-for-pfizer-lilly-innovent-bayer-gsk-daewon

Pfizer & Lilly’s JAK Inhibitors Drug; FDA Approves Lilly’s Bebtelovimab; GSK’s Benlysta; Daewon’s Non-steroidal Anti-inflammatory Drug; Lilly & Innovent’s Lung Cancer Drug; Bayer’s Asundexian

Pfizer and Lilly's JAK Inhibitors Safety Concerns Prompt Europe to Investigate the Drug Class The risk of heart problems associated with the use of JAK inhibitors has called the entire drug class into question. In September, the FDA announced that it would require safety warnings for drugs such as Pfizer's Xeljanz, Eli Lilly's Olumiant, and AbbVie's Rinvoq. It is now up to Europe to conduct a more thorough examination of the treatments. The European Medicines Agency has announced on Friday that it's Pharmacovigilance Risk Assessment Committee (PRAC) would look at all JAK inhibitors following the recent findings of a clinical trial of the Xeljanz, which sho...

Explore More...

Gilead to buy Forty Seven; Akrevia Therapeutics unveils new identity; FDA approved pyrimethamine

US approval to Lundbeck’s Vyepti for preventive migraine care; Esperion’s cholesterol-lowering drug Nexletol receives FDA nod; Karius – a start-up company – raises USD 165 Million – strengthens it liquid biopsy testing

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Analysis & Perspective

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Pfizer & Lilly’s JAK Inhibitors Drug; FDA Approves Lilly’s Bebtelovimab; GSK’s Benlysta; Daewon’s Non-steroidal Anti-inflammatory Drug; Lilly & Innovent’s Lung Cancer Drug; Bayer’s Asundexian

Gilead to buy Forty Seven; Akrevia Therapeutics unveils new identity; FDA approved pyrimethamine

US approval to Lundbeck’s Vyepti for preventive migraine care; Esperion’s cholesterol-lowering drug Nexletol receives FDA nod; Karius – a start-up company – raises USD 165 Million – strengthens it liquid biopsy testing

Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics’ pancreatic cancer a bust

J&J collaborates with BARDA; Virus kills pancreatic cancer cells; ALX raises USD 105 million for CD47 drug

Good news for Kite’s KTE-X19, and Aquestive’s Libervant; and a commercialization deal between ReForm Biologics, MilliporeSigma

Immune cells for age-related diseases; Regeneron’s antibody for 2019-nCoV; FDA nods for hydrogel injection

First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint; Insmed’s shares Soares

Annovis announces IPO results; Conatus merges with Histogen; Novartis discontinues its generic journey

More Views & Analysis

Acceleron Pharma’s drug sotatercept touches the phase 2 mark; GT Medical receives nod for GammaTile; New treatment strategy for Parkinson’s disease

Tepezza receives approval; a new way to treat Alzheimer’s

Imfinzi combo gets ODD; Mayzent gets EU nod; Positive results of VP-102

Thumbs down to NKTR-181, Lilly expands its insulin armamentarium

Eli Lilly to acquire Dermira, Boehringer buys Enleofen’s IL-11 platform, Biogen acquires Pfizer’s Alzheimer’s drug

Novome raises USD 33M, Buyout of Bioniz, Adagene raises USD 69M

Nunaps raises USD 4.2M; Arcutis files for USD 100M IPO

Roche, Sarepta collaborates; FDA approval for Merck’s Ervebo, and Allergan’s Ubrelvy

Subscribe to our Updates

Daily

Weekly

Monthly